HIV heart risk: can two drug combos tame weight and cholesterol?

NCT ID NCT06317051

Ongoing Disease control Sponsor: Kirby Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This study tests two drug combinations in 300 people with HIV who have gained weight or have high cholesterol. One part compares dapagliflozin (a diabetes drug) to a placebo for weight loss. The other compares a two-drug statin combo to a single statin for lowering cholesterol. The goal is to reduce heart disease risk in this group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dapagliflozin, Rosuvastatin/Ezetimibe, Pitavastatin
What this could lead to: If successful, this could offer a way to manage weight and cholesterol in people with HIV, reducing their risk of heart disease.
What could go wrong: This is a mid-stage trial with 300 participants, so results may not apply to everyone. The drugs may cause side effects like muscle pain or kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease Weight Gain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS WEIGHT GAIN

Contacts and locations

Locations

Austin Health

Melbourne, Victoria, 3084, Australia
CART-CRS

Chennai, Tamil Nadu, 600113, India
Desmond Tutu Health Foundation

Cape Town, 7925, South Africa
HIV-NAT

Bangkok, Thailand
Hospital Ramos Mejía

Buenos Aires, Argentina
Infectious Diseases Institute, Makerere University

Kampala, Uganda
Institute of Human Virology, Nigeria

Abuja, Nigeria
St Vincent's Hospital

Sydney, New South Wales, 2010, Australia
Universiti Malaya Medical Centre

Kuala Lumpur, Malaysia
University of Zimbabwe Clinical Research Centre

Harare, Zimbabwe

More trials for these conditions

Other studies related to the condition(s) this trial covers.